Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2022-08-01
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-25 (study day 17); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 31); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 54); relationship: not assessed; serious criteria: life-threatening
severe
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 71); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 72); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 152); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.